HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease.
HIFiBiO integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders.
HIFiBiO was founded in 2013 and is based in Paris, Ille-de-France, France with additional offices in Cambridge, Massachusetts & Shanghai, China.
HIFiBiO is developing a robust pipeline of novel therapeutic antibodies that mobilize the human immune system to combat cancer and autoimmune disorders. With a sharp focus on regulatory T cells and Myeloid-derived suppressor cells, our programs aim to modulate multiple immune cell types and key pathways.
HIFiBiO's platform combines high throughput, single cell, functional-based screening of entire B cell populations with barcoded next generation sequencing and rapid DNA synthesis to deeply mine tens of millions of B cells in a typical immune response for rare antibody drugs.
HiFiBiO applies their proprietary single-cell functional antibody screening CelliGO™ platform, unique immune profiling Drug Intelligent Science (DIS™) capabilities and state-of-the-art antibody profiling and engineering process to enable rapid identification of differentiated therapeutic molecules and to significantly enhance clinical probability of success.
HiFiBiO is backed by leading investors including IDG Capital, Sequoia Capital China, LYFE Capital, & Legend Star among others. The company raised $67M in its latest funding of a "Series C" round on Aug 28, 2019. This brings HiFiBiO's total funding to $104.5M to-date.